InVivo Therapeutics (OTC:NVIV) is getting a top-line shuffle after chairman, CEO and CFO Francis Reynolds resigned suddenly due to a "medical condition."
InVivo Therapeutics
Hansen Medical pulls in $93M, shares surge 20% | Wall Street Beat
Hansen Medical (NSDQ:HNSN) said it inked an equity financing deal for up to $93 million with a consortium of investors including Oracle Investment Management and private equity player Jack Schuler, a co-founder of Crabtree Partners.
InVivo tackles debt, aims for up-listing to a national exchange
Massachusetts-based spinal devices maker InVivo Therapeutics (OTC:NVIV) hopes to up-list to a national stock exchange now that it’s has paid down significant debts.
Pluristem launches Phase I clinical trial to treat tendonitis with stem cells
Pluristem (NSDQ:PSTI) announced a new Phase I clinical trial to treat chronic tendonitis with the company’s PLX-PAD stem cell therapy.
Cell therapy has traditionally been used in cancer and cardiac treatments, but Pluristem is now applying the technology to sports-related injuries, where it has seen an increased interest among athletes and orthopedic surgeons.
InVivo Therapeutics gains on Q1 results
Shares of InVivo Therapeutics (OTC:NVIV) area up today despite wider 1st-quarter operating losses, as investors react to news that the medical device company will seek a listing on either the New York Stock Exchange or the NASDAQ exchange.
InVivo expects to raise $10.4M from early warrants call
Massachusetts-based spinal devices maker InVivo Therapeutics (OTC:NVIV) announced an early call for exercise of warrants issued in 2010, expecting to raise $10.4 million.
Under the terms of the warrants, InVivo has the right to call for early exercise because NVIV shares have traded above $2.80 per share for 20 consecutive days, which occurred yesterday.
Topera details $25M Series C round | Wall Street Beat
Topera said a new backer, New Enterprise Assoc., led a $25 million Series C round first reported by MassDevice.com last month, with an unnamed "strategic industry partner" joining the round.
Invivo starts first human trial for spinal cord scaffold
InVivo Therapeutics (OTC:NVIV) said the FDA has given the company the green light to begin the first human clinical studies of its bioploymer scaffold, which treats traumatic spinal cord injury.
The Cambridge, Mass.-based company said it is gearing up for safety studies in 5 patients over 15 months, and is shooting for Institutional Review Board (IRB) approval at Massachusetts General Hospital.
InVivo Therapeutics’ spinal cord scaffold wins FDA nod
InVivo Therapeutics (OTC:NVIV) said the FDA deemed its biopolymer scaffold, designed to treat spinal cord injuries, to be a humanitarian use device.
The designation means the InVivo scaffold can seek expedited approval from the FDA for a pivotal trial of the device. HUD-based exemptions cover devices aimed at treating rare diseases and health problems, so-called "orphan" conditions.
InVivo updates bid for FDA OK of spinal trauma treatment
InVivo Therapeutics (OTC:NVIV) hopes to begin testing in humans in an open-label safety and efficacy study now that it’s updated its submission for an investigational device exemption submission for its spinal cord injury treatment.
InVivo filed the original investigational device exemption application in July 2011, but has yet to be approved.